I did some quick sums - we could’ve sold it as 6% Spodumene at around A$27m if we converted it at market rates (USD6500-7000).
This does not take into account the cost of converting it.
Essentially we haven’t really lost much in selling it as DSO rather than concentrate.
Ann: Inaugural DSO Tender, page-10
Add CXO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $210.0M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 5627 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.3¢ | 50000 | 1 |
View Market Depth
| Last trade - 09.44am 19/11/2024 (20 minute delay) ? |
| CXO (ASX) Chart |
Day chart unavailable